Arcturus Therapeutics (ARCT) Competitors $12.44 -0.46 (-3.57%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$12.46 +0.02 (+0.12%) As of 07:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT vs. TVTX, ANIP, MESO, OCUL, BGM, GPCR, AMPH, CALT, AUPH, and CVACShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Travere Therapeutics (TVTX), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Ocular Therapeutix (OCUL), Qilian International Holding Group (BGM), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Its Competitors Travere Therapeutics ANI Pharmaceuticals Mesoblast Ocular Therapeutix Qilian International Holding Group Structure Therapeutics Amphastar Pharmaceuticals Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals CureVac Travere Therapeutics (NASDAQ:TVTX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership. Do insiders & institutionals believe in TVTX or ARCT? 94.5% of Arcturus Therapeutics shares are held by institutional investors. 4.2% of Travere Therapeutics shares are held by insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer TVTX or ARCT? Arcturus Therapeutics received 355 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 66.42% of users gave Arcturus Therapeutics an outperform vote while only 61.94% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes9661.94% Underperform Votes5938.06% Arcturus TherapeuticsOutperform Votes45166.42% Underperform Votes22833.58% Which has preferable earnings & valuation, TVTX or ARCT? Arcturus Therapeutics has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$273.53M4.71-$111.40M-$2.81-5.17Arcturus Therapeutics$131.27M2.57-$29.73M-$2.53-4.92 Which has more risk & volatility, TVTX or ARCT? Travere Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500. Is TVTX or ARCT more profitable? Arcturus Therapeutics has a net margin of -36.39% compared to Travere Therapeutics' net margin of -137.90%. Arcturus Therapeutics' return on equity of -22.39% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-137.90% -1,636.87% -55.95% Arcturus Therapeutics -36.39%-22.39%-14.81% Does the media favor TVTX or ARCT? In the previous week, Travere Therapeutics had 4 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 14 mentions for Travere Therapeutics and 10 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.47 beat Travere Therapeutics' score of 0.55 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate TVTX or ARCT? Travere Therapeutics presently has a consensus price target of $32.14, suggesting a potential upside of 121.37%. Arcturus Therapeutics has a consensus price target of $53.50, suggesting a potential upside of 330.06%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcturus Therapeutics is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 SummaryArcturus Therapeutics beats Travere Therapeutics on 14 of the 19 factors compared between the two stocks. Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$337.39M$6.85B$5.57B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-5.608.7827.1320.06Price / Sales2.57255.64412.28157.10Price / CashN/A65.8538.2534.64Price / Book1.196.557.064.70Net Income-$29.73M$143.93M$3.23B$247.88M7 Day Performance4.45%3.84%2.86%2.63%1 Month Performance7.33%11.20%9.05%6.36%1 Year Performance-59.95%4.18%31.39%14.05% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics3.2664 of 5 stars$12.44-3.6%$53.50+330.1%-61.6%$337.39M$131.27M-5.60180News CoverageAnalyst RevisionGap UpTVTXTravere Therapeutics2.5276 of 5 stars$15.52+3.3%$31.79+104.8%+105.4%$1.38B$273.53M-3.79460Trending NewsAnalyst ForecastAnalyst RevisionANIPANI Pharmaceuticals4.2288 of 5 stars$61.91+5.4%$80.13+29.4%-3.3%$1.34B$674.07M-112.56600High Trading VolumeMESOMesoblast2.3496 of 5 stars$10.38-2.4%$18.00+73.4%+62.8%$1.33B$5.67M0.0080News CoverageAnalyst RevisionOCULOcular Therapeutix3.8423 of 5 stars$8.11+1.2%$16.25+100.4%+75.7%$1.29B$59.65M-6.14230Positive NewsBGMQilian International Holding GroupN/A$12.90-3.7%N/AN/A$1.25B$25.10M0.00298Positive NewsGap UpGPCRStructure Therapeutics2.5 of 5 stars$21.79+0.1%$79.86+266.5%-54.6%$1.25BN/A-29.45136News CoveragePositive NewsAnalyst RevisionAMPHAmphastar Pharmaceuticals3.6678 of 5 stars$25.38-1.3%$32.33+27.4%-36.7%$1.20B$730.66M8.461,620CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals3.3372 of 5 stars$7.96+1.5%$11.50+44.5%+45.8%$1.08B$247.30M-53.06300Positive NewsAnalyst RevisionCVACCureVac4.4171 of 5 stars$4.63+3.6%$11.00+137.6%-4.2%$1.04B$523.70M8.42880Positive News Related Companies and Tools Related Companies Travere Therapeutics Alternatives ANI Pharmaceuticals Alternatives Mesoblast Alternatives Ocular Therapeutix Alternatives Qilian International Holding Group Alternatives Structure Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Calliditas Therapeutics AB (publ) Alternatives Aurinia Pharmaceuticals Alternatives CureVac Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARCT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
